Minimally Invasive Biopsy Techniques Market to Grow at 10.22% CAGR through 2029

The demand for non-invasive treatment procedures and increasing incidence of cancer is expected to drive the Global Minimally Invasive Biopsy Techniques Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “Minimally Invasive Biopsy Techniques Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2019-2029F”, the Global Minimally Invasive Biopsy Techniques Market stood at USD 12.47 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 10.22% through 2029.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Minimally Invasive Biopsy Techniques Market”

The expansion of the Global Minimally Invasive Biopsy Techniques Market is being propelled by several key drivers, signifying a substantial transformation in diagnostic methodologies. A primary catalyst for this growth is the escalating global incidence of cancer and chronic diseases, necessitating the adoption of more precise and less invasive diagnostic methods. This surge in demand underscores the indispensable role played by minimally invasive biopsy techniques, which offer patients and healthcare providers a safer and more efficient means of diagnosis compared to conventional methods.

The relentless pace of technological advancements is a significant catalyst driving the expansion of the market for minimally invasive biopsy techniques. Particularly noteworthy are the strides made in imaging modalities and biopsy instruments, which have ushered in a new era in diagnostic procedures. These innovations have brought about a fundamental transformation in the landscape of minimally invasive biopsy techniques, substantially augmenting their precision and efficacy.

These advancements have not gone unnoticed, garnering considerable interest and adoption among both healthcare professionals and patients. Healthcare providers are increasingly turning to these advanced techniques, recognizing their potential to revolutionize diagnostic practices and improve patient outcomes. Patients, too, are becoming more receptive to minimally invasive biopsy procedures, drawn by the promise of reduced discomfort and quicker recovery times compared to traditional methods.

As these technological innovations continue to evolve and become more refined, the market for minimally invasive biopsy techniques is expected to experience further growth and expansion. With ongoing advancements paving the way for even greater precision and efficiency, the future of minimally invasive biopsy procedures looks promising, offering new possibilities for enhanced diagnosis and treatment in healthcare settings worldwide.

Furthermore, there has been a discernible increase in awareness among both patients and healthcare professionals regarding the myriad benefits of minimally invasive procedures. As understanding of these techniques deepens, their adoption rates continue to climb, further driving market growth. Additionally, supportive government initiatives aimed at promoting minimally invasive diagnostic procedures, coupled with ongoing enhancements in healthcare infrastructure, are playing pivotal roles in propelling the overall development of the market.

These factors paint a promising trajectory for the Global Minimally Invasive Biopsy Techniques Market, teeming with opportunities for further growth and innovation. As technology continues to advance and awareness spreads, the market is poised for sustained expansion. The overarching objective remains steadfastly focused on delivering safer, more efficient, and more accessible diagnostic solutions to patients worldwide, thereby ensuring improved outcomes and heightened quality of care on a global scale.

The Global Minimally Invasive Biopsy Techniques Market is segmented into product offered, technique, circulating biomarker, application, end user, regional distribution, and company

Based on circulating biomarker, in the global minimally invasive biopsy techniques market, Circulating Tumor DNA (ctDNA) is emerging as a dominant player. CtDNA, also known as cell-free tumor DNA, is genetic material shed by tumor cells into the bloodstream. Its dominance stems from its potential to provide valuable insights into a patient's cancer profile through a simple blood draw, thereby enabling non-invasive and real-time monitoring of tumor dynamics. CtDNA analysis offers clinicians a minimally invasive means of assessing tumor mutational status, detecting minimal residual disease, monitoring treatment response, and predicting disease progression. These attributes make ctDNA a preferred biomarker for liquid biopsy-based diagnostic approaches, driving its prominence in the global Minimally Invasive Biopsy Techniques Market.

Given its multifaceted utility and non-invasive nature, ctDNA has emerged as the preferred biomarker for liquid biopsy-based diagnostic approaches. Its prominence in the global Minimally Invasive Biopsy Techniques Market is driven by the increasing recognition of its clinical utility and the growing demand for minimally invasive diagnostic solutions. As the field continues to advance and technologies evolve, ctDNA is poised to remain a cornerstone of liquid biopsy-based diagnostics, driving innovation and shaping the future of cancer care.

Based on region, North America leads the global Minimally Invasive Biopsy Techniques Market due to several key factors. Its advanced healthcare infrastructure, equipped with state-of-the-art facilities, enables precise biopsy procedures. The region's commitment to technological innovation fosters the development and adoption of groundbreaking techniques. Favorable reimbursement policies ensure widespread access to these advanced technologies, driving market growth. Additionally, North America's robust research and development landscape, involving academic institutions and key market players, continuously evolves and refines minimally invasive biopsy technologies, further solidifying its leadership position in the global market.

Major companies operating in Global Minimally Invasive Biopsy Techniques Market are:

• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific, Inc.
• PerkinElmer Inc.
• QIAGEN NV
• Guardant Health, Inc.
• Veracyte, Inc.
• Myriad Genetics, Inc.
• Biocept, Inc.
• NeoGenomics Laboratories, Inc.
• Adaptive Biotechnologies Corporation

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The minimally invasive biopsy techniques use real-time analysis of tumor-derived material extracted from various body fluids, which is a promising tool that could enhance the current practice by assisting clinicians in disease screening, satisfying patients' needs for the best treatment, and monitoring treatment response and resistance mechanisms. Besides, cancer has significant potential for the future Application of artificial intelligence (AI) in medicine, not only for early and accurate diagnosis but also treatment, therapy, and illness prognosis prediction. Rapidly developing minimally invasive techniques hold considerable promise for the efficient, risk-free treatment of benign breast lesions. The expense of surgical treatments requiring general anesthesia is reduced by the fact that percutaneous treatment of breast tumors is typically carried out in an office setting under local anesthetic. The utilization of minimally invasive techniques for biopsy is expected to show promising growth in the future period with more technological advancement and is expected to become the most preferred way for biopsy, globally.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Minimally Invasive Biopsy Techniques Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Offered (Tests, Kits & Consumables, Instruments), By Technique (Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others {Breath Biopsy etc.}), By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Others {miRNA, CTECs, circRNA etc.}), By Application (Clinical and Therapeutic), By End User (Hospitals & Clinics, Ambulatory Care Center, Academic & Research Institutions), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Minimally Invasive Biopsy Techniques Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Minimally Invasive Biopsy Techniques Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com